Your browser doesn't support javascript.
loading
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Aldridge, Bree B; Barros-Aguirre, David; Barry, Clifton E; Bates, Robert H; Berthel, Steven J; Boshoff, Helena I; Chibale, Kelly; Chu, Xin-Jie; Cooper, Christopher B; Dartois, Véronique; Duncan, Ken; Fotouhi, Nader; Gusovsky, Fabian; Hipskind, Philip A; Kempf, Dale J; Lelièvre, Joël; Lenaerts, Anne J; McNamara, Case W; Mizrahi, Valerie; Nathan, Carl; Olsen, David B; Parish, Tanya; Petrassi, H Michael; Pym, Alexander; Rhee, Kyu Y; Robertson, Gregory T; Rock, Jeremy Michael; Rubin, Eric J; Russell, Betsy; Russell, David G; Sacchettini, James C; Schnappinger, Dirk; Schrimpf, Michael; Upton, Anna M; Warner, Peter; Wyatt, Paul Graham; Yuan, Ying.
Afiliação
  • Aldridge BB; Tufts University, Boston, MA, USA.
  • Barros-Aguirre D; GlaxoSmithKline, Tres Cantos, Spain.
  • Barry CE; National Institutes of Health, Bethesda, MD, USA.
  • Bates RH; GlaxoSmithKline, Tres Cantos, Spain.
  • Berthel SJ; Panorama Global, Seattle, WA, USA.
  • Boshoff HI; National Institutes of Health, Bethesda, MD, USA.
  • Chibale K; University of Cape Town, Cape Town, South Africa.
  • Chu XJ; Global Health Drug Discovery Institute, Beijing, China.
  • Cooper CB; Global Alliance for TB Drug Development, New York, NY, USA.
  • Dartois V; Hackensack Meridian Health Center for Discovery & Innovation, Nutley, NJ, USA.
  • Duncan K; Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Fotouhi N; Global Alliance for TB Drug Development, New York, NY, USA.
  • Gusovsky F; Eisai, Andover, MA, USA.
  • Hipskind PA; Lgenia, Fortville, IN, USA.
  • Kempf DJ; AbbVie, North Chicago, IL, USA.
  • Lelièvre J; GlaxoSmithKline, Tres Cantos, Spain.
  • Lenaerts AJ; Colorado State University, Fort Collins, CO, USA.
  • McNamara CW; Calibr, a division of the Scripps Research Institute, La Jolla, CA, USA.
  • Mizrahi V; University of Cape Town, Cape Town, South Africa.
  • Nathan C; Weill Cornell Medicine, New York, NY, USA. cnathan@med.cornell.edu.
  • Olsen DB; Merck & Co., West Point, PA, USA.
  • Parish T; Seattle Children's Research Institute, Seattle, WA, USA.
  • Petrassi HM; Calibr, a division of the Scripps Research Institute, La Jolla, CA, USA.
  • Pym A; Janssen-Cilag, Buckinghamshire, UK.
  • Rhee KY; Weill Cornell Medicine, New York, NY, USA.
  • Robertson GT; Colorado State University, Fort Collins, CO, USA.
  • Rock JM; The Rockefeller University, New York, NY, USA.
  • Rubin EJ; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Russell B; Bill & Melinda Gates Medical Research Institute, Boston, MA, USA.
  • Russell DG; Cornell University, Ithaca, NY, USA.
  • Sacchettini JC; Texas A&M University, College Station, TX, USA.
  • Schnappinger D; Weill Cornell Medicine, New York, NY, USA.
  • Schrimpf M; AbbVie, North Chicago, IL, USA.
  • Upton AM; Evotec, Lyon, France.
  • Warner P; Bill & Melinda Gates Foundation, Seattle, WA, USA.
  • Wyatt PG; Drug Discovery Unit, University of Dundee, Dundee, Scotland.
  • Yuan Y; Global Health Drug Discovery Institute, Beijing, China.
Nat Med ; 27(8): 1333-1337, 2021 08.
Article em En | MEDLINE | ID: mdl-34226736
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Desenho de Fármacos / Antituberculosos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Desenho de Fármacos / Antituberculosos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article